Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$38.59

1.61 (4.35%)

, VRTX

Vertex

$182.39

0.06 (0.03%)

11:33
04/16/19
04/16
11:33
04/16/19
11:33

Piper reiterates $75 target for Crispr after CTX001 gets Fast Track

Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics after the company and partner Vertex (VRTX) announced Fast Track Designation for CTX001 to treat transfusion-dependent beta thalassemia. The analyst believes Crispr's ex vivo approach and biological rational of targeting fetal hemoglobin "de-risk and differentiate" CTX001 from other gene editing players. And he continues to think that first-in-man CTX001 data this year "will serve as an important driver" for Crispr and the gene editing field. Tenthoff says Crispr Therapeutics remains a top for 2019.

CRSP

Crispr Therapeutics

$38.59

1.61 (4.35%)

VRTX

Vertex

$182.39

0.06 (0.03%)

  • 30

    Apr

  • 14

    May

CRSP Crispr Therapeutics
$38.59

1.61 (4.35%)

03/13/19
WBLR
03/13/19
INITIATION
WBLR
Market Perform
Crispr Therapeutics initiated with a Market Perform at William Blair
William Blair analyst Raju Prasad started Crispr Therapeutics with a Market Perform rating. The analyst views the company as the best pure-play on CRISPR technology, but cites competition and gene editing volatility for his neutral rating.
03/14/19
WBLR
03/14/19
INITIATION
WBLR
Market Perform
William Blair starts Crispr Therapeutics with Market Perform, $39 fair value
William Blair analyst Raju Prasad last night initiated coverage of Crispr Therapeutics with a Market Perform rating and $39 fair value estimate. The analyst acknowledges the innovative nature of the CRISPR/Cas9 discovery but views the most-progressed indications, targeted-beta-thalassemia and sickle cell with CTX001 and allogeneic T-cell therapy for hematological malignancies, as "hyper-competitive spaces where the company is behind the leaders in clinical development." As such, Crispr Therapeutics' current valuation adequately reflects the stage of clinical development for its product candidates, Prasad tells investors in a research note.
04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Piper Jaffray says Crispr Therapeutics remains a top pick for 2019
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $75 price target on Crispr Therapeutics, and added that Crispr remains a top pick for 2019, after the company announced the expansion of its wholly-owned allogeneic CAR-T pipeline at the American Association for Cancer Reseach, or AACR. Tenthoff said he expects more preclinical CAR-T data at the American Society of Gene and Cell Therapy, or ASGCT, in April. The analyst believes the biggest driver for the company remains "first-in-man Phase I/II CTX001 data in Beta-thal and potentially Sickle Cell Disease" this year.
04/11/19
EVER
04/11/19
INITIATION
Target $46
EVER
Outperform
Crispr Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Crispr Therapeutics with an Outperform rating and a price targets of $46. The analyst says the company's ex vivo gene therapy gives it a low risk path to market while it continues to refine its delivery systems required for in vivo editing. Mehrotra also cites Crispr's potential to have several programs in clinic in 2019-2020, along with strong partnerships and clinical execution that "could lead to significant near term clinical news flow."
VRTX Vertex
$182.39

0.06 (0.03%)

03/26/19
HCWC
03/26/19
NO CHANGE
Target $15
HCWC
Buy
Proteostasis regiments warrant further investigation, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein says it was his hope that the Proteostasis (PTI) compounds would generate a 10 ppFEV1 improvement and provide either a legitimate competitor for Vertex (VRTX) or identification of molecules that could serve as possible add-ons to other shelved or early development modulators. Factually, none of the dose cohorts measured at either seven-day or 14-days after treatment generated a 10 ppFEV1 improvement, Fein tells investors in a research note. However, due to the complete lack of any competition to the Vertex "strangle-hold" on the cystic fibrosis landscape as well as the "apparent if not overwhelming desire," at least outside of the U.S., for a second option, the Proteostasis regiments warrant further investigation, says the analyst. He believes yesterday's data may provide an opportunity in more severe cystic fibrosis patients. Fein keeps a Buy rating on Proteostasis with a $15 price target. The stock closed yesterday down 68%, or $2.76, to $1.31.
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
03/26/19
03/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Strong Buy from Market Perform at Raymond James , to Hold from Sell at Loop Capital, and to Sector Weight from Underweight at KeyBanc. 2. BB&T (BBT) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor saying after meeting with CEO of SunTrust (STI), he remains positive on the merger and the combined stock. 3. Vertex (VRTX) upgraded to Outperform from Market Perform at William Blair with analyst Y. Katherine Xu citing expectations that the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. 4. Allegiant Travel (ALGT) upgraded to Outperform from Neutral at Macquarie with analyst Susan Donofrio citing her meetings with its management last week. 5. TransAlta (TAC) upgraded to Buy from Hold at TD Securities with analyst John Mould saying Brookfield Renewable Partners (BEP) $750M investment in TransAlta improves the company's financial flexibility, accelerates its ability to return capital to shareholders and advance the coal-to-gas conversion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
EVER
04/11/19
INITIATION
Target $183
EVER
In Line
Vertex initiated with an In Line at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Vertex with an In-Line rating and a price target of $183. The analyst says the company has "great science, execution, and management", but its multiple is the highest relative to its peers and appears to be "priced to perfection". Mehrotra adds that the debate around EU pricing will intensify, becoming a "bigger and longer headwind".

TODAY'S FREE FLY STORIES

SGEN

Seattle Genetics

$71.10

1.69 (2.43%)

21:00
04/25/19
04/25
21:00
04/25/19
21:00
Recommendations
Seattle Genetics analyst commentary at Piper Jaffray »

Seattle Genetics Q1 marks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 20

    May

  • 31

    May

  • 06

    Jun

TCBK

TriCo Bancshares

$39.57

-0.47 (-1.17%)

20:35
04/25/19
04/25
20:35
04/25/19
20:35
Earnings
TriCo Bancshares reports Q1 EPS 74c, consensus 71c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

XOM

Exxon Mobil

$82.25

0.51 (0.62%)

, CVX

Chevron

$117.93

-0.38 (-0.32%)

20:25
04/25/19
04/25
20:25
04/25/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

XOM

Exxon Mobil

$82.25

0.51 (0.62%)

CVX

Chevron

$117.93

-0.38 (-0.32%)

CL

Colgate-Palmolive

$68.64

-0.2 (-0.29%)

ADM

Archer Daniels

$41.77

-0.99 (-2.32%)

WY

Weyerhaeuser

$26.27

-0.07 (-0.27%)

AAL

American Airlines

$33.36

-0.64 (-1.88%)

LEA

Lear

$146.64

-6.455 (-4.22%)

IPG

Interpublic Group

$22.28

-0.26 (-1.15%)

GT

Goodyear Tire

$19.56

-0.54 (-2.69%)

AN

AutoNation

$39.43

0.91 (2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 30

    Apr

  • 01

    May

  • 08

    May

  • 10

    May

  • 16

    May

  • 17

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 29

    May

  • 04

    Jun

  • 12

    Jun

  • 13

    Nov

ATRC

AtriCure

$28.19

0.21 (0.75%)

20:18
04/25/19
04/25
20:18
04/25/19
20:18
Recommendations
AtriCure analyst commentary at Piper Jaffray »

AtriCure growth story…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 22

    May

NOW

ServiceNow

$260.95

18.54 (7.65%)

19:43
04/25/19
04/25
19:43
04/25/19
19:43
Recommendations
ServiceNow analyst commentary at Jefferies »

ServiceNow price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

GFI

Gold Fields

$3.74

0.08 (2.19%)

19:34
04/25/19
04/25
19:34
04/25/19
19:34
Upgrade
Gold Fields rating change at BMO Capital »

Gold Fields upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

19:28
04/25/19
04/25
19:28
04/25/19
19:28
Hot Stocks
Watchdog finds at least 78,000 reviews removed from Amazon »

Watchdog Which? said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

EHTH

eHealth

$62.23

0.32 (0.52%)

, MAT

Mattel

$12.30

-0.25 (-1.99%)

19:02
04/25/19
04/25
19:02
04/25/19
19:02
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

EHTH

eHealth

$62.23

0.32 (0.52%)

MAT

Mattel

$12.30

-0.25 (-1.99%)

KNL

Knoll

$20.57

-0.22 (-1.06%)

GRUB

GrubHub

$69.83

0.53 (0.76%)

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

F

Ford

$9.41

-0.17 (-1.77%)

COF

Capital One

$88.09

0.3 (0.34%)

SFLY

Shutterfly

$42.30

-0.65 (-1.51%)

COLM

Columbia Sportswear

$104.45

-0.65 (-0.62%)

SWN

Southwestern Energy

$4.03

-0.13 (-3.13%)

DFS

Discover

$77.48

0.43 (0.56%)

LOGM

LogMeln

$84.32

0.085 (0.10%)

BABY

Natus Medical

$25.20

0.54 (2.19%)

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

TMUS

T-Mobile

$72.68

-0.67 (-0.91%)

SBUX

Starbucks

$77.07

0.65 (0.85%)

ATEN

A10 Networks

$7.28

0.14 (1.96%)

PFPT

Proofpoint

$131.35

3.56 (2.79%)

FII

Federated Investors

$33.57

0.605 (1.84%)

INTC

Intel

$57.59

-1.13 (-1.92%)

BEAT

BioTelemetry

$59.26

0.52 (0.89%)

BGG

Briggs & Stratton

$13.61

-0.44 (-3.13%)

SKYW

SkyWest

$58.44

-1.31 (-2.19%)

SGEN

Seattle Genetics

$71.10

1.69 (2.43%)

VCRA

Vocera

$31.31

0.36 (1.16%)

ILMN

Illumina

$318.91

4.47 (1.42%)

INT

World Fuel Services

$31.15

0.1 (0.32%)

BMRN

BioMarin

$85.40

-0.06 (-0.07%)

MHK

Mohawk

$130.69

-3.46 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 28

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 20

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 24

    Jul

  • 06

    Aug

  • 03

    Sep

  • 23

    Oct

  • 13

    Nov

ATEN

A10 Networks

$7.28

0.14 (1.96%)

19:00
04/25/19
04/25
19:00
04/25/19
19:00
Earnings
A10 Networks sees Q2 EPS (8c) to 0c, two estimates 0c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ATEN

A10 Networks

$7.28

0.14 (1.96%)

18:59
04/25/19
04/25
18:59
04/25/19
18:59
Earnings
A10 Networks reports Q1 EPS (9c), two estimates (7c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CNC

Centene

$50.20

0.04 (0.08%)

18:44
04/25/19
04/25
18:44
04/25/19
18:44
Hot Stocks
Centene CEO: Most people are happy with their healthcare »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 29

    May

  • 23

    Jul

APHA

Aphria

$7.64

-0.17 (-2.18%)

18:23
04/25/19
04/25
18:23
04/25/19
18:23
Hot Stocks
Green Growth Brands says offer for Aphria has expired »

Green Growth Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGN

Align Technology

$296.77

-0.35 (-0.12%)

18:21
04/25/19
04/25
18:21
04/25/19
18:21
Hot Stocks
Align Technology CEO: We are enjoying good growth in North America »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

  • 05

    Jun

AAPL

Apple

$205.28

-1.82 (-0.88%)

18:21
04/25/19
04/25
18:21
04/25/19
18:21
Periodicals
Several veterans leave Apple's design team, WSJ reports »

Apple's design team…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    Jun

FB

Facebook

$193.23

10.59 (5.80%)

18:18
04/25/19
04/25
18:18
04/25/19
18:18
Hot Stocks
Canadian agency says probe shows Facebook broke privacy law »

Canada's Office of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

NOV

National Oilwell

$26.44

-0.04 (-0.15%)

18:17
04/25/19
04/25
18:17
04/25/19
18:17
Earnings
National Oilwell reports Q1 EPS (20c), consensus (8c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 22

    May

  • 13

    Nov

FB

Facebook

$193.23

10.59 (5.80%)

18:16
04/25/19
04/25
18:16
04/25/19
18:16
Hot Stocks
Ireland's DPC opens statutory inquiry into Facebook »

Ireland's Data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

FB

Facebook

$193.23

10.59 (5.80%)

18:15
04/25/19
04/25
18:15
04/25/19
18:15
Hot Stocks
NY AG to investigate Facebook's collection of user email contact databases »

New York State Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

18:09
04/25/19
04/25
18:09
04/25/19
18:09
Hot Stocks
Amazon.com says had 'a lot of good customer wins' in Q1 »

Says: Usage growth higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

FIBK

First Interstate

$41.94

-0.63 (-1.48%)

18:08
04/25/19
04/25
18:08
04/25/19
18:08
Earnings
First Interstate reports Q1 EPS 69c, consensus 72c »

Reports Q1 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 02

    May

F

Ford

$9.41

-0.17 (-1.77%)

18:03
04/25/19
04/25
18:03
04/25/19
18:03
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says improving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

PUB

People's Utah Bancorp

$28.02

0.09 (0.32%)

18:01
04/25/19
04/25
18:01
04/25/19
18:01
Earnings
People's Utah Bancorp reports Q1 EPS ,55c consensus 55c »

Reports Q1 NII $26.91M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 14

    May

  • 15

    May

AEGN

Aegion

$19.44

-0.58 (-2.90%)

17:57
04/25/19
04/25
17:57
04/25/19
17:57
Hot Stocks
Aegion subsidiary awarded three contracts valued at $13M total »

Aegion announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

17:55
04/25/19
04/25
17:55
04/25/19
17:55
Hot Stocks
Amazon.com says will spend $800M in Q2 to move to one-day Prime delivery »

Says: Need to build out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

F

Ford

$9.41

-0.17 (-1.77%)

17:53
04/25/19
04/25
17:53
04/25/19
17:53
Hot Stocks
Ford CFO: Encouraged by progress made in China toward return to profitability »

Sees FY19 revenue growth,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.